Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management

References

• Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am. 2019;33(1):1–12.
   PubMed Web of Science ®Google Scholar
• Genders RE, Weijns ME, Dekkers OM, et al. Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta‐analysis. J Eur Acad Dermatol Venereol. 2019;33(5):828–841.
   PubMed Web of Science ®Google Scholar
• Keyal U, Bhatta AK, Zhang G, et al. Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2019;80(3):765–773.
   PubMed Web of Science ®Google Scholar
• Skin Cancer Foundation: Skin Cancer Facts & Statistics [Internet]. The Skin Cancer Foundation, 2019. [cited 2019 Oct 21]. Available from: https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/
   Google Scholar
• National Comprehensive Cancer Network: Squamous Cell Skin Cancer, NCCN Guidelines Version 1.2020, in NCCN Clinical Practice Guidelines in Oncology [Internet]. 2019. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#site
   Google Scholar
• Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081–1086.
   Web of Science ®Google Scholar
• Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–966.
   PubMed Web of Science ®Google Scholar
• Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2017;92(6):890–898.
   PubMed Web of Science ®Google Scholar
• Feinstein S, Higgins S, Ahadiat O, et al. A retrospective cohort study of cutaneous squamous cell carcinoma with lymph node metastasis: risk factors and clinical course. Dermatol Surg. 2019;45(6):772–781.
   PubMed Web of Science ®Google Scholar
• Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma outcomes: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(4):419–428.
   PubMed Web of Science ®Google Scholar
• Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin. 2011;29(2):161–174.
   PubMed Web of Science ®Google Scholar
• Yom SS. Integrating the management of nodal metastasis into the treatment of nonmelanoma skin cancer. Semin Radiat Oncol. 2019;29(2):171–179.
   PubMed Web of Science ®Google Scholar
• Karia PS, Morgan FC, Ruiz ES, et al. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. JAMA Dermatol. 2017;153(8):781.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, National Institutes of Health: Melanoma of the Skin - Cancer Stat Facts [Internet]. SEER [cited 2019 Oct 24]. Available from: https://seer.cancer.gov/statfacts/html/melan.html.
   Google Scholar
• Amin MB, Edge S, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing, 2017.
   Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Ruiz ES, Karia PS, Besaw R, et al. Performance of the American Joint Committee on cancer staging manual, 8th edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2019;155(7):819.
   PubMed Web of Science ®Google Scholar
• Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402.
   PubMed Web of Science ®Google Scholar
• Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma. JCO. 2014;32(4):327–334.
   PubMed Web of Science ®Google Scholar
• Roscher I, Falk RS, Vos L, et al. Notice of retraction and replacement: Roscher et al. validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol. 2018;154(4)428–434.
   PubMed Web of Science ®Google Scholar
• Karia PS, Morgan FC, Califano JA, et al. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Dermatol. 2018;154(2):175.
   PubMed Web of Science ®Google Scholar
• Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2020. DOI:10.1016/j.jaad.2020.04.088
   Web of Science ®Google Scholar
• Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–183.
   PubMed Web of Science ®Google Scholar
• Cook RW, Middlebrook B, Wilkinson J, et al. Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. Diagn Pathol. 2018;13(1):13.
   PubMed Web of Science ®Google Scholar
• Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med. 2019;8(5):2205–2212.
   PubMed Web of Science ®Google Scholar
• Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207–1217.
   PubMed Web of Science ®Google Scholar
• Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–1603.
   PubMed Web of Science ®Google Scholar
• Scope A, Essat M, Pandor A, et al. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review. Int J Technol Assess Health Care. 2017;33(1):32–45.
   PubMed Web of Science ®Google Scholar
• Ward S, Scope A, Rafia R, et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(44):1–302.
   PubMed Web of Science ®Google Scholar
• McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. BCTT. 2017;9:393–400.
   Web of Science ®Google Scholar
• Alford AV, Brito JM, Yadav KK, et al. The use of biomarkers in prostate cancer screening and treatment. Rev Urol. 2017;19:221–234.
   PubMedGoogle Scholar
• Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol. 2018;31(S1):143–155.
   Web of Science ®Google Scholar
• Vargas-Salas S, Martínez JR, Urra S, et al. Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocr Relat Cancer. 2018;25(3):R163–R177.
   PubMed Web of Science ®Google Scholar
• Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 2015;111(1):43–50.
   PubMed Web of Science ®Google Scholar
• Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32(9):1599–1604.
   PubMed Web of Science ®Google Scholar
• Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists’ clinical management decisions. J Drugs Dermatol. 2017;16(5):428–431.
   PubMed Web of Science ®Google Scholar
• Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. J Skin. 2018;2(2):111–121.
   Google Scholar
• Aaberg TM, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–2460.
   PubMedGoogle Scholar
• Plasseraud KM, Cook RW, Tsai T, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol. 2016;2016:1–9.
   Web of Science ®Google Scholar
• Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560–578.
   PubMed Web of Science ®Google Scholar
• Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–261.
   PubMed Web of Science ®Google Scholar